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ABSTRACT
We have determined the expression of transforming
growth factor a (TGFa), amphiregulin (AR), CRIPTO, the
epidermal growth factor receptor (EGFR), erbB-2, erbB-3,
and tumor angiogenesis in a series of 195 patients with stage
I-lilA non-small cell lung cancer (NSCLC) treated with
radical surgery to define their usefulness as prognostic in-
dicators of survival. A variable degree of specific staining in
cancer cells was observed for the three growth factors and
for the three growth factor receptors in the majority of
NSCLC patients. A statistically significant association be-
tween overexpression of TGFc, AR, and CRIPTO was oh-
served. Enhanced expression of AR was significantly corre-
bated with enhanced expression of erbB-2 and advanced
T-stage. A direct association was also detected for overex-
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pression of TGFc and of erbB-2 or erbB-3, respectively. Sex,
tumor size, nodal status, stage, microvessel count, as a meas-
ure of neovascularization, and AR overexpression signifi-
cantly correlated with overall survival at univariate analysis.
In a Cox multivariate analysis, the only characteristics with
an independent prognostic effect on OAS were microvessel
count [relative hazard (RH), 6.61; P < 0.00001), nodal status
(RH, 1.59; P 0.0013), and AR overexpression (RH, 1.72;
P = 0.02). These results suggest that evaluation of neoan-
giogenesis and of certain growth factors, such as AR, can be
useful in addition to conventional pathological staging to
select high-risk NSCLC patients who may benefit from post-
surgical systemic therapies.
INTRODUCTION
Complete surgical resection is the only potentially curative
treatment for NSCLC3 patients. Pathological staging of NSCLC
represents the most accurate evaluation currently available of
clinical outcome in patients who have undergone surgical re-
section. However, the survival of NSCLC patients with early
stage operable disease is not satisfactory. Approximately 30-
40% of pathological stage I patients have disease recurrence and
eventually die following apparently curative surgery. To im-
prove the results of surgery, systemic adjuvant chemotherapy
following radical surgery has been proposed in NSCLC patients.
However, the impact of adjuvant systemic therapies on survival
is not completely defined (1). In this respect, the identification
of novel pathological and/or biological prognostic variables in
addition to disease stage could allow the selection of high-risk
NSCLC patients who may benefit of adjuvant systemic postsur-
gical treatment (2).
The potential prognostic role of several biological param-
eters, including oncogenes, such as Ki-ras (3-5), tumor sup-
pressor genes, such as p53 (6-9), and cancer cell proliferative
activity (10-13), has been investigated in NSCLC. However,
conflicting results on the independent prognostic role of these
variables have been reported (2). Peptide growth factors are
involved in regulating normal epithelial cell proliferation and
differentiation (14). EGF and structurally related growth factors,
such as TGFa and AR, are potent mitogens for several human
3 The abbreviations used are: NSCLC, non-small cell lung cancer;
MVC, microvesseb count; EGF, epidermal growth factor; EGFR, EGF
receptor; TGFa, transforming growth factor a; AR, amphiregulin;
PCNA. proliferating cell nuclear antigen; RH, relative hazard; CI, con-
fidence interval; OAS, overall survival.
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epithelial cell types, including breast, colon, ovary, and lung,
and have been implicated in human cancer development and
progression through autocrine and paracrine pathways ( IS).
EGF, TGFct, and AR bind to EGFR (1 5). It has been recently
shown that EGFR dimerization or heterodimerization with ci-
ther erbB-2, erbB-3, or erbB-4, which arc EGFR-relatcd growth
factor receptors. is needed for intracellular signal transduction
induced by these ligands ( 16). Although structurally rebated to
EGF-like peptides, CRIPTO is a growth factor that acts through
a not yet identified cell membrane receptor (15). CRIPTO is
overexpressed in human coborectal and breast cancers as corn-
pared to normal epitheliurn and is an autocrinc growth factor for
colon and breast cancer cells ( 17-22). EGFR or erbB-2 over-
expression has been correlated with a worse prognosis in
NSCLC patients, although their independent prognostic role is
still controversial (23-27). However, no extensive study on the
frequency of expression and on the prognostic value of the
various EGF-like growth factors and of their specific receptors
has been performed in NSCLC.
Several peptide growth factors that are locally secreted by
tumor cells, including the EGF-bike growth factors, also regulate
cancer development and progression by inducing tumor neovas-
cularization through the paracrine stimulation of normal endo-
thelial cell proliferation (28). In this respect, the formation of
novel blood vessels is an important step in cancer development
and progression because it is essential for providing adequate
oxygen and nutrient supply to the growing tumor mass and for
initiating metastatic spreading (29). Furthermore, the count of
microvessels in the most intense areas of neovascubarization has
been suggested as a prognostic marker in patients with different
human cancers, including malignant melanoma, breast, head and
neck, prostatic, ovarian, gastric. and lung carcinomas (29-37).
In the present study, we evaluated the expression of TGFa,
AR, CRIPTO, EGFR, erbB-2, and erbB-3 and the intensity of
tumor angiogcncsis in a series of 195 stage I-lilA NSCLC
patients treated with radical surgery without any pre- or post-
surgical local or systemic therapy in an attempt to define their
usefulness as prognosticators of survival in operable NSCLC.
PATIENTS AND METHODS
Patients and Tumor Tissues. One hundred ninety-five
consecutive NSCLC patients who had undergone curative sur-
gical resection at the Department of Surgery, University of Pisa,
from March 199 1 to December 1994 were studied. There were
175 males and 20 females with a median age of 64 years (range,
41-80 years). As of August 31, 1996, the median follow-up
period for living patients was 36 months (range, 19-64
months). The patients presented no detectable metastases in
distant organs at the moment of surgery. They had not received
either chemotherapy or radiation therapy before surgery. No
adjuvant treatment was given following radical surgery. Sur-
vival was calculated as the period from surgery to death. Tumors
specimens obtained at surgery were formalin-fixed and paraffin-
embedded for histological and immunohistochemicab process-
ing. Tumors were classified according to the WHO histological
classification (38) and following the guidelines of the American
Joint Committee on Cancer Staging.
Immunohistochemistry and Evaluation of Immunoper-
oxidase Staining. Formalin-fixed, paraffin-embedded tissue
sections (5 jim) were deparaffinized in xylenc and rehydrated in
a graded series of ethanol. The slides were then treated for 30
mm a 20#{176}Cwith methanol containing 0.3% hydrogen peroxide
to block any endogenous peroxidase activity. After several
washes with PBS, the sections were blocked for 45 mm with
10% goat serum or with 10% horse serum, washed with PBS,
and incubated overnight with the appropriate primary antibody
at 4#{176}C.Sections were then washed three times with PBS and
treated with an appropriate secondary biotinylated goat antibody
(I :200 dilution, Vectastain ABC kit, Vector Laboratories, Bur-
bingame, CA) for 30 mm, as previously reported (23). Following
several washes with PBS, the slides were reacted for 30 mm
with avidin-biotinylated horseradish peroxidase H complex,
rinsed twice in PBS, and incubated for 2 mm in 0.05% diami-
nobenzidine and in 0.01% hydrogen peroxide as described pre-
viously (23). The slides were then rinsed in distilled water,
counterstained with hcmatoxilin, and mounted. The following
antibodies were used in this study. An anti-CRIPTO rabbit
antiserum, CR-67, was raised against a 17-mer peptide corre-
sponding to amino acid residues 97-1 13 of the human CRIPTO
protein, which represent the COOH terminus of the 37 amino
acid EGF-like region, and was used at a 1 :400 dilution, as
described previously (22). An anti-AR rabbit antiserum, AR56,
was generated against a 17-mer peptide corresponding to amino
acid residues 159-175 of the rat AR protein and was used at a
1 :200 dilution (22). An anti-TGFa mouse monoclonal antibody
that was generated using human recombinant TGFa as an im-
munogen (Ab-2, Oncogene Science, Manhasset, NY) was used
at a 1 : 100 dilution. Each antibody was specific for TGFa, AR,
or CRIPTO and did not cross-react with the other two EGF-
related peptides (22). An anti-erbB-2 rabbit antiserum that was
raised against a synthetic peptide (2lN) representing residues
1243-1255 of the predicted protein sequence was used at a
1 :200 dilution (22). An anti-EGFR mouse monoclonal antibody
that was generated using human EGFR as an immunogen (Tri-
ton, Alameda, CA) was used at a 1 : 100 dilution (23). An
anti-erbB-3 mouse monoclonab antibody, RTJ2, was raised
against a synthetic peptide corresponding to a portion of the
cytoplasmic domain of the human c-erbB-3 protein and was
used at a 1 :200 dilution, as described previously (39). Each
antibody was specific for EGFR, erbB-2, or erbB-3 and did not
cross-react with the other two related receptors (22, 23, 39). An
anti-CD34 monocbonal antibody (clone QB-END1O, Novocas-
tra, Newcastle, United Kingdom) was used for microvessel
staining at a 1 : 100 dilution (40). For evaluation of tumor cell
proliferative activity, the anti-PCNA PC 10 mouse monoclonal
antibody (Novocastra) was used at a 1 :200 dilution. Nonspecific
staining was evaluated for each specimen using either a similar
concentration of preimmune rabbit serum or IgG, or by adsorb-
ing the primary antibody with the appropriate immunogenic
peptide. To determine the percentage of positive cells, at least
1000 cancer cells per slide were counted and scored. For MVC
determination, a single microvessel was defined as any brown
immunostained endothelial cell separated from adjacent mi-
crovessebs, tumor cells, and mesenchymal cells. Each sample
was examined under low power (X 10 objective lens and X 10
ocular lens) to identify the three regions of the section with the
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highest number of microvessels. A X250 field (X25 objective
lens and X 10 ocular lens; 0.74 mm2 per field) in each of these
three areas was counted, and the average counts of the three
fields were recorded. Large vessels with thick muscular walls
were excluded from the counts.
Statistical Analysis. The association between the differ-
cnt pathological and biological characteristics was studied by
the use of contingency tables. Statistical significance was eval-
uated by the Pearson x2 test. Univariate survival analysis for the
role of each prognostic variable on survival was estimated
according to the Kaplan-Mcier product-limit method (41). The
statistical significance of the differences in survival distribution
among prognostic groups was evaluated by the log-rank test
(42). For multicategorical ordinal variables, a test for trend was
used. For TGFa, AR, CRIPTO, EGFR, erbB-2, erbB-3, and
PCNA, the cutoff values in the series of 195 NSCLC patients
were used to distinguish between bow- and high-expressing
tumors. MVC was considered either as a dichotomous variable,
using the median value of 20 microvessels in the series of 19S
NSCLC patients as a cutoff or using five groups of increasing
microvessel number/sample (1-10, 11-20, 21-30, 31-40, and
41-100), Mubtivariate analysis was carried out by the Cox
proportional hazards regression model (43). The Cox model was
used to determine among the clinicopathobogical and biological
characteristics that had significantly affected survival at the
univariate analysis, such as stage, T status, nodal status, MVC,
and AR, those with an independent prognostic robe. Covariate
selection was performed by a stepwise procedure using a max-
imum likelihood ratio test for backward elimination. MVC was
introduced into this model as a continuous variable after a
log-transformation due to its skewed distribution. For covariatcs
retained into the final model, RHs with 95% CIs were estimated.
All Ps represent two-sided tests of statistical significance. Ps 
0.05 were considered statistically significant. All analyses were
performed with the BMDP New System statistical package,
version 1.0 for Microsoft Windows (BMDP Statistical Software,
Los Angeles, CA).
RESULTS
Clinicopathological Characteristics. One hundred
ninety-five NSCLC patients (175 males and 20 females) with a
median age of64 years (range, 41-80) were studied. There were
1 16 patients with squamous cell carcinoma (59.5%), 66 patients
with adenocarcinoma (33.8%), and 1 3 patients with large cell
anaplastic carcinoma (6.7%). According to the degree of differ-
entiation, 44 (22.6%) were well differentiated (Gl) cancers, 77
(39.5%) were moderately differentiated (G2) cancers, and 74
(37.9%) were poorly differentiated (03) carcinomas. Forty-two
(21.5%) tumors were classified as Tl, 132 (67.7%) as T2, and
21 (10.8%) as T3. Metastatic involvement of hilar lymph nodes
(NI) was present in 30 (15.4%) patients, whereas mediastinal
lymph nodes (N2) were involved in 40 (20.5%) patients. Ab-
sence of lymph node metastatic involvement (NO) was observed
in 125 (64.1%) patients. The majority ofthe cases was classified
as stage I ( 1 1 5, 59%), whereas 25 ( I 2.8%) cases were stage II,
and 55 (28.2%) cases were stage lIlA. At the time of analysis,
122 (62.6%) patients were alive and 73 (37.4%) patients were
dead.
Table I Expression of TGFa, AR, CRIPTO, EGFR, erbB-2, and
erbB-3 in 195 NSCLC patients
Immunohistochemical evaluation was performed as described in
‘Patients and Methods.’ Samples were considered positive when spe-
cific immunostaining was detected in 5% cancer cells.
Positive/total
cases (%)
% positive tumor cells,
median (range)
TGFa 193/195 (99) 65 (0-80)
AR 152/195(77.9) 35 (0-75)
CRIPTO 178/195(91.3) 50(0-90)
EGFR 158/195(81) 45 (0-90)
erbB-2 119/195(61) 25 (0-80)
erbB-3 166/195 (85.1 ) 45 (0-80)
Expression of Growth Factors, Growth Factor Recep-
tors, and Measurement of Neovascularization. TGFa, AR,
CRIPTO. EGFR, erbB-2, and erbB-3 expression was evaluated
by immunohistochemistry in the series of 195 NSCLC patients.
As shown in Table I , the majority of lung cancer samples
expressed specific immunostaining for the three EGF-like
growth factors and for the three erbB-relatcd growth factor
receptors. The intensity of staining within a single cancer spec-
imen was heterogeneous for all proteins. ranging from 0 to
75-90% of the cancer cells. Immunoreactivity was limited to
cancer cells because there was very little or no specific staining
in the surrounding stroma or in capillary endothelial cells (data
not shown). We next evaluated whether any correlation could
exist between growth factor or growth factor receptor expres-
sion in cancer specimens and the clinicopathological character-
istics of the 195 NSCLC patients. As illustrated in Table 2. a
statistically significant direct association between overexpres-
sion of TGFa, AR, and CRIPTO was observed. Furthermore,
enhanced expression of AR was significantly correlated with
enhanced expression of erbB-2 and advanced T stage. A direct
association was also detected for overexpression of TGFa and
erbB-2 or erbB-3, respectively. A higher frequency of CRIPTO
overexpression was found in adenocarcinomas, whereas EGFR-
overexpressing tumors were significantly associated with the
squamous cell carcinoma histological subtype.
MVC, as an indicator of neovasculanzation within the
primary tumor, was determined by immunohistochemical stain-
ing of endothelial vessels using an anti-CD34 monoclonal anti-
body (40). Heterogeneous MVC distribution ranging between 3
and 100 microvessels/tumor sample with a median of 20 was
observed in the NSCLC patients. Higher MVC was significantly
associated with lymph nodal involvement (P = 0.0004) but not
with any other clinicopathological or biological variable ana-
lyzed (data not shown).
Univariate Analysis of Association of Clinicopathologi-
cal and Biological Characteristics with Survival. The prog-
nostic impact of clinicopathological and biological parame-
ters on patient survival was evaluated by univariate analysis.
As shown in Table 3 and Fig. 1, female sex (P = 0.032),
greater tumor size (P = 0.008), nodal status (P < 0.00001),
and advanced stage (P < 0.00001) were significantly asso-
ciated with a worse OAS. MVC, analyzed either as a dichot-
omous variable using the median value of 20 microvessels as
a cutoff or as five groups of increasing microvessel numbcr/
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Table 2 Association of TGFa, AR, CRIPTO, EGFR, erbB-2, and erbB-3 expression with clinicopathobogical and biological characteristics
Associations between pairs of parameters were evaluated using contingency tables and were analyzed for statistical significance with the
Pearson’s 2 test. The median values of MVC, TGFa, AR, CRIPTO, EGFR, erbB-2, and erbB-3 were used as cutoffs to discriminate between high-
and low-expressing tumors. Data are presented as percentage of high-expressing tumors for TGFa, AR, CRIPTO, EGFR, erbB-2, and erbB-3 within
each clinicopathological or biological parameter. Ps  0.05 were considered as statistically significant.
n” TGFa AR CRIPTO EGFR erbB-2 erbB-3 MVC
Tumor status
Tl 42 57.1% 26.2% 42.8% 40.5% 50% 50% 40.5%
T2 132 43.2% 52.3% 41.7% 50.8% 50% 47.7% 48.5%
T3 21 42.8%
P=0.27
47.6%
P=O.013
47.6%
P=0.88
38.1%
P=0.34
52.4%
P=0.98
57.1%
P=0.72
61.9%
P=0.27
Node status
NO 125 48% 42.4 40.8% 41.6% 50.4% 51.2% 37.6%
NI 30 40% 53.3 50% 60% 56.7% 53.3% 70%
N2 40 45%
P=O.72
52.5
P=0.37
42.5%
P=O.66
55%
P=0.lO
45%
P=O.63
40%
P=0.41
65%
P=0.0004
Histology
Squamous 116 42.2% 39.6% 36.2% 56.9% 49.1% 52.6% 43.1%
Adenocarcinoma 66 53% 57.6% 57.6% 34.8% 54.5% 40.9% 54.5%
Anaplastic 13 46.1%
P=O.37
46.1%
P=0.07
23.1%
P=0.007
23.1%
P=0.003
38.5%
P=0.53
61.5%
P=0.21
61.5%
P=0.20
Grading
01 44 47.7% 45.5% 45.5% 50% 50% 50% 45.5%
G2 77 51.9% 48% 44.1% 49.4% 55.8% 50.6% 46.7%
G3 74 39.2%
P=O.28
44.6%
P=O.91
39.2%
P=O.75
43.2%
P=0.69
44.6%
P=0.38
47.3%
P=0.91
5 1.4%
P=O.78
MVC
2O 101 47.5% 46.5% 42.6% 47.5% 51.5% 48.5%
>20 94 44.7%
P = 0.68
45.7%
P = 0.91
42.5%
P = 0.99
46.8%
P = 0.92
48.9%
P = 0.72
50%
P = 0.83
TGFa
65 105 36.2% 34.3% 47.6% 41.9% 41.9% 49.5%
>65 90 57.8%
P - 0.003
52.2%
P = 0.012
46.7%
P = 0.89
60%
P = 0.012
57.8%
P = 0.027
46.7%
P = 0.69
AR
35 105 36.2% 29.5% 46.7% 40.9% 45.7% 48.6%
>35 90 57.8%
P = 0.003
57.8%
P = 0.0001
47.8%
P = 0.88
61.1%
P = 0.005
53.3%
P = 0.29
47.8%
P = 0.91
CRIPTO
50 112 38.4% 33.9% 49.1% 51.8% 51.8% 48.2%
>50 83 56.6%
P = 0.012
62.6%
P = 0.0001
44.6%
P = 0.53
48.2%
P = 0.62
45.8%
P = 0.41
48.2%
P = 0.99
EGFR
45 103 46.6% 45.6% 44.7% 54.4% 46.6% 48.5%
>45 92 45.6%
P = 0.89
46.7%
P = 0.88
40.2%
P = 0.53
45.6%
P = 0.22
52.2%
P = 0.44
47.8%
P = 0.92
erbB-2
25 97 37.1% 36.1% 44.3% 51.5% 43.3% 49.5%
>25 98 55.1%
P = 0.012
56.1%
P = 0.005
40.8%
P = 0.62
40.8%
P = 0.22
55.15
P = 0.09
46.9%
P = 0.72
erbB-3
45 99 38.4% 42.4% 45.4% 44.4% 44.4% 47.5%
>45 96 54.2%
P = 0.027
50%
P = 0.29
39.6%
P = 0.41
50%
P = 0.44
56.2%
P = 0.09
48.5%
P = 0.83
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“ No. of patients.
sample (1-10, 11-20, 21-30, 31-40, and 41-100), was a
highly significant predictor of OAS (P < 0.00001; Table 3
and Fig. 1, C and D). Age, histological sybtype, histological
grading, and tumor proliferative activity, assessed by PCNA
nuclear staining, were not able to predict disease outcome
(Table 3). Among the EGF-like growth factors and the erbB-
related receptors, AR overexpression was the only parameter
significantly associated with a worse OAS (P = 0.01; Table
3 and Fig. lE).
Multivariate Analysis of Association of Clinicopatho-
logical and Biological Characteristics with Survival. A
multivariate analysis was performed to define the variables with
independent prognostic value with respect to survival. The din-
icopathological parameters that were associated with OAS at
univariate analysis, such as stage, T status, nodal status, MVC,
and AR, were introduced in a Cox proportional hazards regres-
sion analysis. Using a backward stepwise procedure, covariates
without independent prognostic significance were eliminated
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Table 3 Univariate analysis for OAS
The five categories for MVC are as follows: 1. 3-10; 2, 1 1-20; 3,
21-30; 4, 31-40; 5, 41-100 microvessels tumor sample. For TGFa, AR,
CRIPTO, EGFR, erbB-2, erbB-3, and PCNA, the cutoff values in the
195 NSCLC patients series were used to distinguish between low- and
high-expressing tumors. The statistical significance of the differences in
survival distribution among prognostic groups was evaluated by the
log-rank test. For multicategorical ordinal variables a test for trend was
used. Ps  0.05 were considered statistically significant.
Observed/expected
Cases deaths P
0.032
0.39
175 0.98
20 1.88
109 0.91
86 1.11
42 0.48
132 1.15
21 1.43
125 0.67
30 1.50
40 2.16
115 0.66
25 1.36
55 1.81
116 0.85
66 1.28
13 1.02
44 0.99
77 0.92
74 1.10
101 0.46
94 1.79
38 0.55
63 0.41
38 1.35
40 2.20
16 2.03
105 0.97
90 1.03
105 0.74
90 1.33
112 0.84
83 1.19
103 0.97
92 1.03
97 0.94
98 1.06
99 0.91
96 1.09
106 1.13
89 0.84
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Sex
Male
Female
Age
64 years
>64 years
Tumor status
Tl
T2
T3
Node status
NO
NI
N2
Stage
II
lIlA
Histology
Squamous
Adenocarcinoma
Anaplastic
Grading
01
02
03
MVC
>20
MVC
2
3
4
5
TGFa
65
>65
AR
35
>35
CRIPTO
:50
>50
EGFR
:s45
>45
erbB-2
25
>25
erbB-3
45
>45
PCNA
35
>35
a Test for trend.
from the model. Nodal status, MVC, and AR were the only
characteristics to retain an independent prognostic influence on
OAS (Table 4), with MVC having the strongest impact (RH,
6.61 ; P < 0.0001) as compared to nodal status (RH, 1 .59; P =
0.0013) or to AR (RH, 1.72; P = 0.02).
DISCUSSION
Growth factors can regulate cancer development and pro-
gression through several mechanisms. These include autono-
mous uncontrolled growth as a result of the autocrinc production
of endogenous growth factors that activate specific receptors
localized on cancer cell membrane and induction of tumor
vascularization due to paracrine stimulation of normal host
endothebial cells by angiogenic growth factors secreted by can-
cer cells. The EGF family of growth factors, including EGF,
0.008” TGFa, AR, and CRIPTO, plays an important role in human
breast and coborectal cancer ( 15). Experimental evidence has
been provided that TGFa and AR, through the activation of
<0.00001” EGFR, function as autocrine growth factors also for both normal
and malignant human bronchial epithelial cells (44). Moreover,
EGFR expression is generally low in normal bronchial epithe-
<0.00001” hum, whereas it is enhanced in preneoplastic and neoplastic
bronchial lesions, and therefore, it has been proposed as an early
marker of neoplastic transformation (45). The potential prog-
nostic role of TGFa, AR, and EGFR and of the closely related
0.19 erbB-2 growth factor receptor has been investigated in human
NSCLC in preliminary pilot studies (15). However, no conclu-
sive information on the prognostic impact of these biological
0.78 parameters has been obtained thus far. Furthermore, no data are
yet available on the expression of the EGF-like growth factor
CRIPTO and of the EGFR-rclated erbB-3 growth factor recep-
<0.00001 tor in human NSCLC.
To our knowledge, this is the first extensive immunohis-
tochemical analysis of the expression of TGFa, AR, CRIPTO,
<0.00001”
EGFR, erbB-2, and erbB-3 in a large group of stage I-lIlA
completely resected NSCLC patients for which survival data
and several clinicopathological and biological parameters, in-
cluding evaluation of tumor proliferative activity and tumor
0 8 angiogenesis, were evaluated. In this study, we found that the. majority of NSCLC sampl s expressed relatively high levels of
the three EGF-bike growth factors and of the three EGFR-rebated
0.01 cell membrane receptors. Furthermore, a statistically significant
direct correlation between overexpression of TGFa, AR, and
0 14  CRIPTO and between overexpression of TGFa and erbB-2 or
. erbB-3 was observed in this series of patients. These results are
similar to those previously reported for human breast and cob-
0.80 rectal cancer (18-19, 22). Among these biological parameters,
enhanced AR expression was the only variable to be signifi-
0.62 cantly correlated with a reduced OAS in the series of 195 stage
I-lilA NSCLC patients at a univariate analysis. The other din-
icopathobogical and biological characteristics that correlated
0.43 with survival at univariate analysis were sex, postsurgical stag-
ing, tumor size, metastatic lymph node involvement, and MVC,
0.22 as a measure of tumor angiogenesis. More importantly, only
nodal status, MVC, and AR overexpression were shown to be as
independent prognostic indicators of OAS.
These results are in support of the clinical relevance of
measuring tumor-induced neovascularization in NSCLC. We
Research. 
on March 7, 2018. © 1998 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
246 Tumor Angiogenesis and Growth Factors in NSCLC
U)
0
0
.0
10
.0
0
a.
A B
I .00
 0,75
0
0
, 0.50
.0
10
.0
0
a. 0,25
0.00
0
C D
I .00
 0,75
0
0
‘ 0.50
.0
10
.0
0
a. 0,25
0.00
12 24 36 48 60 0 12 24 36 48 60
Months
MVC Low
Months
 n’,,.  
I .00
 0,75
0
0
, 0,50
.0
Ca
.0
0
a. 0.25
0,00
12 24 36 48 60 0 12 24 36 48 60
Months Months
E
1,00
AR Low
AR High
0 12 24 36
Months
48 60
0,75
0
0
, 0,50
(a
.0
0
o_ 0.25
Fig. I Kaplan-Meier OAS estimates in relationship to tumor status (A), nodal status (B), MVC considered as a dichotomous variable (C) or as a
five-category variable (D), and AR expression (E). A MVC of 20 was the median cutoff value in the series of 195 NSCLC patients for considering
high or low tumor angiogenesis. D, the five categories for MVC were as follows: 1, 3-10; 2, 11-20; 3. 21-30; 4, 31-40; and 5, 41-100
microvessels/tumor sample. Thirty-five % positive tumor cells was the median cutoff in the series of 195 NSCLC patients for considering bow or high
AR expressing tumors. The Ps for each estimate were as follows: A, P 0.008; B, P < 0.00001; C, P < 0.00001; D, P < 0.00001; and E, P = 0.01.
PS  0.05 were considered statistically significant.
have previously reported that high MVC, assessed by tumor
staining with a monoclonal antibody against factor Vill-related
antigen, was significantly correlated with metastatic spreading
and with a worse prognosis in selected or relatively small series
of NSCLC patients (32-33, 37). For example, in a group of 70
stage I-HI NSCLC patients with a median follow-up of 46
months in which some biological parameters, such as p53, bcl-2
expression, and tumor proliferative activity, were evaluated,
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4 Unpublished results.
Table 4 Multivariate analysis for OAS
The three variables that retained an independent prognostic effect on survival using the Cox proportional hazards model are represented in the
final model. Stage was considered as I, II, and lilA. Node status was evaluated as NO, Nb , and N2. MVC was considered as a continuous variable
after a bog transformation. AR was considered as a dichotomous variable using the median of 35% positive tumor cells/sample as cutoff for low- and
high-expressing tumors. 3, regression coefficient. Ps  0.05 were considered statistically significant.
Covariate 13 SE x2 P RH (95% CI)
Starting model
Stage 1.15 0.28
T status 2.09 0.15
Nodal status 6.24 0.01
MVC 19.42 <0.00001
AR 3.72 0.05
Final model
Nodal status 0.4658 0.1403 10.36 0.0013 1.59 (1.20-2.11)
MVC 1.8879 0.4336 19.65 <0.00001 6.61 (2.78-15.72)
AR 0.5437 0.2398 5.24 0.02 1.72 (1.07-2.78)
MVC was the only biological variable with an independent
prognostic impact on survival (35). Harpole et a!. (36) have
recently demonstrated that tumor angiogenesis was the most
significant independent prognostic factor in a retrospective anal-
ysis of 275 stage I completely resected NSCLC patients in
which erbB-2 and p53 expression were also found as independ-
ent prognosticators. However, our study failed to demonstrate a
prognostic effect of erbB-2 expression, as well as of p53 cx-
pression4 on patient survival. Giatromanolaki et a!. (34) have
shown that in 107 stage I NSCLC patients, highly vascularized
tumors as evaluated by anti-CD31 staining significantly corre-
lated with a worse survival. We have recently obtained similar
results in a series of 227 stage I NSCLC patients (46).
The results of the present study demonstrate that in stages
I-lilA NSCLC patients who were treated with potentially cura-
tive surgery, the evaluation of some biological characteristics of
the primary tumor may be helpful in defining groups of patients
with a high risk of relapse who could benefit of adjuvant
systemic treatments. MVC is the more important biological
variable, and it deserves to be evaluated in larger prospective
studies and in clinical trials of postsurgical adjuvant therapy. In
this respect, we have recently demonstrated in a prospective
study in which 407 NSCLC patients were evaluated that MVC
is an independent prognostic indicator of survival (47). Further-
more, the present report is the first to demonstrate the independ-
ent prognostic role of AR overexpression in NSCLC. It is
interesting to note that although AR overexpression was signif-
icantly correlated with a more advanced tumor size, AR over-
expression, but not tumor size, maintained an independent prog-
nostic value in a Cox model of survival. Our results need to be
validated prospectively in other independent series of patients.
However, a clinically relevant aspect of our findings is the
observation that autocrine and paracrine regulatory pathways
involving EGF-like growth factors and EGFR-related receptors
are frequently operative in human NSCLC. With the clinical
development of specific drugs, such as anti-growth factor re-
ceptor humanized monoclonal antibodies and modified anti-
sense oligodeoxynucleotides, that interfere with these growth
stimulatory pathways (48-52) and of specific antiangiogenic
drugs that can block endothelial cell proliferation (53), evalua-
tion of the expression of growth factors and their receptors and
assessment of tumor-induced neovascularization could allow
researchers to select NSCLC patients in whom to test the anti-
tumor activity of these agents used alone or in combination with
conventional cytotoxic drugs.
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